W B Deal, E Sanders. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » AdultCarrier State/drug therapyClinical Trials as TopicDrug Resistance, MicrobialFemaleHumansMeningococcal Infections/drug therapyNeisseria meningitidis/drug effectsNeisseria meningitidis/isolation & purificationPlacebosRifampin/administration & dosageRifampin/adverse effectsRifampin/pharmacologyRifampin/therapeutic useSulfadiazine/pharmacology
Substances: See more » PlacebosSulfadiazineRifampin
Year: 1969 PMID: 4980025 DOI: 10.1056/NEJM196909182811203
Source DB: PubMed Journal: N Engl J Med ISSN: 0028-4793 Impact factor: 91.245